15
2021-07
Suzhou, July 15, 2021-- 真人直营投注网站 (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries (the"Collaboration Regions"). Kintor and Fosun Pharma Development will collaborate on the development, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.
13
2021-07
Suzhou, July 13, 2021 - 真人直营投注网站 (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects. GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally which has entered the clinical stage. Following China Center for Drug Evaluation (CDE) 's IND approval for GT20029's clinical study in April 2021, the clinical study in the US is about to start.
11
2021-07
Suzhou, July 11, 2021 - 真人直营投注网站 (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide (KX-826)’s phase II clinical trial for the treatment of androgenetic alopecia (AGA).
15
2021-06
Suzhou, June 15, 2021 - 真人直营投注网站 (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved the phase III clinical trial of proxalutamide to treat male patients with mild or moderate COVID-19 symptoms on June 11, 2021[1].
18
2021-05
Suzhou, May 18, 2021 - 真人直营投注网站 (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's phase III clinical trial of hospitalised COVID-19 patients to be conducted, which will recruit both male and female patients. Separately, the FDA agreed to the addition of female patients to its ongoing proxalutamide phase III clinical trial in outpatients with mild to moderate COVID-19 illness. The company will publish and update details of these pivotal studies at ClinicalTrials.gov.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn